| Literature DB >> 21106440 |
Michael A Gelman1, Jeffrey S Glenn2.
Abstract
Therapy for hepatitis C virus (HCV) infection is on the cusp of a new era. Until now, standard-of-care therapy has involved interferon (IFN) and ribavirin. With the first successful Phase III trials of specific targeted antiviral therapy for HCV (STAT-C) compounds, as well as three trials in progress giving the first glimpse of IFN-free combinations of STAT-C agents, this review looks ahead to the new classes of anti-HCV agents currently in clinical development. Successful pharmacologic control of HIV and TB frames the discussion, as well as consideration of the mutation frequency of HCV replication. Maximizing synergy between agents and minimizing cumulative toxicity will be critical to the design of future IFN-free STAT-C regimens. Copyright ÂEntities:
Mesh：
Substances：
Year: 2010 PMID： 21106440 PMCID： PMC3085044 DOI： 10.1016/j.molmed.2010.10.005
Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951